|Bid||224.48 x 800|
|Ask||224.94 x 800|
|Day's Range||223.00 - 230.00|
|52 Week Range||76.59 - 331.68|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||264.20|
Baylor College of Medicine Assistant Professor Dr. Sara Andrabi joins Yahoo Finance to discuss the requirement of vaccinations for foreign travelers and other trends amid the COVID-19 pandemic.
If you buy high-quality companies and hang onto them for long periods of time, your chances of growing your initial investment by leaps and bounds goes up significantly. What's more, Novavax's vaccine development platform should allow it to quickly tackle new variants and develop potential combination treatments in the future.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General